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Before the widespread use of HIGHLY ACTIVE ANTIRETROVIRAL
THERAPY (HAART) in the developed world, ∼20–30% of
individuals infected with HIV-1 (referred to as HIV from
this point) developed a range of cognitive and motor
symptoms, including impaired short-term memory,
reduced concentration and leg weakness, that are col-
lectively known as HIV-associated dementia (HAD;
also known as the AIDS dementia complex). These
symptoms often occurred together with behavioural
symptoms, such as personality changes, apathy and
social withdrawal, and HAD could, in its more severe
forms, lead to a nearly vegetative and mute state. The
onset of HAD is correlated with high plasma viral loads,
which accounts for the strong effects of HAART on
reducing its INCIDENCE1, although with the longer lifespan
of patients with HIV, there is increasing PREVALENCE of
HAD. With the use of HAART, a more subtle form 
of central nervous system (CNS) dysfunction — minor
cognitive motor disorder (MCMD) — has either
become more common or is more obvious because it
does not progress to HAD2. In this syndrome, loss of
memory and decreases in computational and other
higher cortical functions are much less pronounced. It
has recently been estimated that ∼10% of HIV-infected
adults have HAD but that MCMD might be several
times more common, involving perhaps as many as
30% of the HIV-infected population. Furthermore, the
clinical presence of MCMD has been associated with
pathological changes in the CNS that are characteristic of
HIV invasion (known as HIV encephalitis), and MCMD
is associated with a worse overall prognosis for HIV-
infected individuals3,4. One potential explanation for the
development of MCMD is that low-level viral replication,
as occurs with all but the most successful HAART regi-
mens, leads to slow progressive neurodegeneration. This
is consistent with the much longer lifespan of treated
patients5 and possibly with the insufficient penetration of
certain antiretroviral drugs into the brain6.
The CNS of children seems to be more vulnerable to
the effects of HIV than that of adults, perhaps because
the paediatric CNS is still developing and contains less
differentiated cell types. Accordingly, the prevalence of
CNS dysfunction in untreated children is ∼50% (and is
known as HIV encephalopathy rather than dementia).
Because the progression of the disease and the cell types
that are involved, but not the response to HAART, differ
in children compared with adults, we focus on adult
disease in this review.
Here, we describe our current knowledge of the
mechanisms that are implicated in dysregulation of nor-
mal cell physiology and in initiation of the neurodegen-
eration that is associated with HIV infection, and we
discuss potential avenues for neuroprotection that could
improve the quality of life for some HIV-positive
patients. Furthermore, because macrophage-mediated
neurodegeneration might also have a role in diseases
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and reverse-transcriptase
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Number of new cases of a
particular disease per year 
per group of population.
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population that is affected by a
particular disease at a given time.
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HIV enters the brain early after systemic infection8,9,
and to do this, it must cross the BBB. The BBB is a
selectively permeable, rather than impermeable, con-
tinuous cellular layer that consists of brain microvascu-
lar endothelial cells; these cells are linked to each other
by tight junctions, which regulate the traffic of cells and
substances from the bloodstream to the CNS. Although
the ‘invasion’ of immune cells across the BBB occurs as
part of immune surveillance10, it is carefully regulated;
therefore, entry of HIV has been the subject of many
studies using animal models and tissue-culture prepa-
rations that mimic the BBB. Using the sheep-specific
lentivirus visna virus as a model of HIV infection,
Haase and colleagues11,12 first proposed that HIV and
other lentiviruses enter the CNS as passengers in cells
that are trafficking to the brain (the ‘Trojan horse’
hypothesis). For HIV — which infects several types of
CD4+ cell that circulate in the blood, such as T cells and
monocytes — this model not only is the most intuitively
appealing but also has the most compelling supporting
evidence (FIG. 2). In situ hybridization and immunohis-
tochemical studies have shown virus accumulation in
the perivascular regions, mainly in CD14+ cells13–19.
There is limited pathological evidence of infection of
endothelial cells, which is consistent with the absence
such as MULTIPLE SCLEROSIS and ALZHEIMER’S DISEASE, the ther-
apeutic strategies discussed might have more general
applications.
Neuroinvasion by HIV
The CNS is susceptible to infection by retroviruses of
various species and by members of the lentivirus family
in particular7. The specific requirements for entry to the
brain and the many cell types in the CNS increase the
complexity of virus–cell interactions in the brain. The
CNS is separated from the rest of the body by the
BLOOD–BRAIN BARRIER (BBB); the cerebrospinal fluid (CSF)
is also separated from the periphery by the blood–CSF
barrier of the CHOROID-PLEXUS epithelium. The structure
of the brain tissue and the BBB are schematically shown
in FIG. 1. In theory, five main cell types — astrocytes,
oligodendrocytes, neurons, perivascular macrophages
and microglia — are susceptible to retroviral infection,
but of these five, the latter two are the most commonly
infected by HIV (TABLE 1). Perivascular macrophages and
microglia arise from bone-marrow-derived cells that
settle in the CNS at various times during development
and throughout adult life; this has implications for the
expression of HIV receptors by these cells and for the
turnover of different subpopulations in the CNS.
MULTIPLE SCLEROSIS 
Neurodegenerative disorder 
that is characterized by
demyelination of bundles of
nerve fibres in the central
nervous system. Symptoms
depend on the site of the 
lesion but include sensory loss,
weakness in leg muscles, speech
difficulties, loss of coordination
and dizziness.
ALZHEIMER’S DISEASE 
Degenerative mental disease that
is characterized by progressive
brain deterioration and
dementia, and by the presence of
senile plaques, neurofibrillary
tangles and neuropil threads.
Disease onset can occur at any
age, and women seem to be
affected more frequently than
men.
BLOOD–BRAIN BARRIER 
Selectively permeable cellular
layer formed by brain
microvascular endothelial 
cells, which are linked by tight
junctions. It is crucial for the
maintenance of homeostasis 
in the brain environment.
CHOROID PLEXUS 
Site of production of
cerebrospinal fluid in the 
adult brain. It is formed by
invagination of ependymal 
cells into the ventricles, which
become highly vascularized.
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Figure 1 | The location of different cell types in the brain. The brain parenchyma is separated from the rest of the body by the
blood–brain barrier, which is a selectively permeable, continuous cellular layer that comprises brain microvascular endothelial cells
linked to each other by tight junctions. It provides anatomical and physiological protection for the central nervous system, and it
strictly regulates the traffic of substances and blood cells into the brain. In the region surrounding the endothelium of brain capillaries,
astrocytes and perivascular macrophages are found. Astrocytes have a crucial role in brain homeostasis, because they establish
contacts with endothelial cells and regulate the permeability of the blood–brain barrier through the release of soluble factors.
Perivascular macrophages are located around blood vessels, and they are replenished through the migration of circulating
monocytes. By contrast, microglia are located in the brain parenchyma and have a much slower turnover than macrophages. In 
the brain parenchyma, oligodendrocytes extend processes that wrap around segments of neuronal axons and produce the myelin
sheath, which consists of lipid- and protein-rich membranes that isolate axons and speed the conduction of nerve impulses.
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Microglia and brain macrophages
In the perivascular region of the brain, several cell types
— mainly astrocytes, perivascular macrophages and
microglia — come into direct contact with virus-infected
cells that have entered the CNS from the blood (TABLE 1).
Of these, perivascular macrophages and microglia are the
most important in HIV infection in the CNS. They
constitute the resident immunocompetent cells of the
brain and respond to all types of insult, ranging from
vascular problems to the protein accumulation that is
associated with some neurodegenerative diseases, such
as Alzheimer’s disease28–31.
of expression of conventional HIV receptors by these
cells, although BBB abnormalities due to HIV infec-
tion have been shown19. In addition, pathological
changes in the brains of patients with HAD correlate
with the presence of activated bone-marrow-derived
cells, such as macrophages20,21. Alternatively, on the
basis of experimental support from in vitro models,
some investigators have suggested that HIV might
enter the CNS by TRANSCYTOSIS of endothelial cells22–24
or by direct infection25–27. However, these mechanisms
are unlikely to account for most of the virus entering
the brain.
TRANSCYTOSIS 
Process of transport of material
across an epithelial layer by
uptake on one side of the
epithelial cell into a coated
vesicle that might then be sorted
through the trans-Golgi network
and transported to the opposite
side of the cell.
Table 1 | Susceptibility of cells of the central nervous system to infection with HIV
Cell type CD4 Chemokine HIV Productive 
antigen receptors susceptibility infection
Perivascular macrophages Yes Yes Yes Yes
Microglia Yes Yes Yes Yes
Astrocytes No Yes Yes No
Oligodendrocytes No Yes In vitro No
Neurons No Yes No No
Brain microvascular endothelial cells No Yes In vitro No
Microglial cell
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Perivascular
macrophage
Basement
membrane
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Figure 2 | HIV neuroinvasion and multinucleated giant-cell formation. a | It has been proposed that HIV enters the brain by 
a ‘Trojan horse’ mechanism, through its presence in infected monocytes that migrate across the blood–brain barrier to replenish
the population of perivascular macrophages. Infected monocytes have an activated phenotype that renders them more prone 
to migrate into tissues than uninfected, activated monocytes. b | All of the virus that is produced in the brain is probably initially
derived from monocytes that have differentiated into perivascular macrophages. Subsequently, microglia might become 
infected and contribute to the production of virus. In addition, activation of microglia might have a role in the mechanisms of
neuropathogenesis. c | The HIV-envelope glycoproteins that are expressed at the surface of infected cells mediate cell-to-cell
fusion with cells that express both CD4 and HIV co-receptor. In the brain, cell-to-cell fusion involves macrophages and microglia,
and it results in the formation of large multinucleated giant cells, or syncytia, that also produce virus before they eventually die.
Their lifespan after fusion is unknown. d | HIV might also enter the brain in infected CD4+ T cells; the contribution of these cells 
to the pool of replicating virus in the brain is still unclear, because genotypic and phenotypic analyses seem to show that viruses
from the brain are more similar to those from monocytes and/or macrophages than to those from T cells. e | Although several
mechanisms for HIV infection of astrocytes have been described, it is generally accepted that infection of these cells is not
productive and that they do not contribute to viral replication. However, both limited expression of HIV genes (by astrocytes) 
and dysregulation of cytokine and chemokine signals (resulting from infection of macrophages or microglia) might contribute 
to astrocytic malfunction and neuropathogenesis.
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CD45 are considered markers for perivascular macro-
phages, then expression of viral antigens by parenchy-
mal microglia (which are CD14–CD45low) is detected
much less frequently than by other brain macrophages
— although parenchymal microglia might harbour
latent infections. The differences might reflect the diffi-
culties in defining an active disease on the basis of static
‘pictures’ that are obtained at the end-point of infec-
tion. In vitro, our own experiments, and those of other
research groups, have clearly indicated that microglia
isolated from the non-inflamed CNS can support
marked replication of HIV41–43 and, as terminally differ-
entiated cells, have a high level of expression of the HIV
co-receptor CC-chemokine receptor 5 (CCR5)44–46.
The expression of viral-envelope glycoproteins 
at the surface of infected cells leads to the formation 
of MNGCs or syncytia, which occurs after the fusion of
infected and uninfected cells (probably of a macrophage
and a microglial cell)13,47,48. In tissue culture, the forma-
tion of syncytia is a common manifestation of HIV
infection and is mediated by the interaction between
the cell-surface-expressed viral glycoproteins and the
cellular receptors, but in vivo, it is observed in only a few
tissues, such as the dermis and in the CNS (FIG. 2). The
presence of MNGCs in the brain tissue of HIV-positive
patients is the main neuropathological finding in HAD
and is considered a hallmark of HIV encephalitis. Only
cells that express both CD4 and an HIV co-receptor can
be fused by the viral glycoproteins; perivascular
macrophages and microglia express CD4, CCR5 and
CXC-chemokine receptor 4 (CXCR4), with CCR5 being
the most important HIV co-receptor for adult microglia
and brain macrophages41,45. However, similar to other
tissue macrophages, brain perivascular macrophages
and microglia express lower levels of CD4 than activated
lymphocytes, and the viral phenotypes that promote
fusion between CNS macrophages and microglia might
therefore be different from those that promote fusion of
lymphocytes49–52. Lymphocytes can also enter the brain
as part of the surveillance mechanism of the CNS10,37,53,
but their contribution to syncytia formation and to the
virus pool in the CNS is unclear. Other cell types in the
CNS do not participate in syncytia formation because
they do not express the appropriate receptors.
Compartmentalization of HIV in the CNS
HIV enters the CNS soon after peripheral infection of
circulating T cells and monocytes8,9. It is unclear whether
it remains in the CNS or is later cleared, only to re-enter
late in infection; various studies support different points
of view. Overall, we favour the hypothesis that HIV pen-
etrates the CNS at various times during infection,
thereby establishing genetically distinct variants in the
brain and perhaps even between various regions of the
brain (REF. 54, and M. Chen and F.G.S., unpublished
observations). Phylogenetic reconstructions have shown
clustering of sequences according to the tissue of origin,
indicating that viruses from the CNS are more closely
related to each other than to viruses originating from
peripheral tissues (that is, the blood, lymph nodes or
spleen) of the same individuals55–59. However, studies
Subtypes of brain macrophage and microglia are
defined by their location and morphology, and by the
presence of specific cell-surface markers. The term
microglia refers mainly to glial cells that are derived from
the MESODERM, and these are clearly distinguishable 
from neurons, astrocytes and oligodendrocytes, all of
which are derived from the ECTODERM32. Microglia have 
a similar antigenic cell-surface phenotype (that is,
express similar cell-surface molecules) to other cells of
the MONONUCLEAR PHAGOCYTIC SYSTEM33; morphologically,
they appear as highly branched cells when in a resting
state (known as ramified microglia) and more-rounded
cells when activated (known as amoeboid microglia).
Amoeboid microglia are absent in the normal adult
brain but can be detected in the developing brain, as
well as in inflammatory or demyelinating conditions in
the fully developed CNS. Perivascular macrophages are
flat and elongated, and are located adjacent to the brain
microvasculature; other macrophage populations are
often identified by their locations in the choroid plexus
or the MENINGES. Although defining an individual cell as 
a macrophage or a microglial cell is difficult, perivascu-
lar macrophages are CD14+CD45+, and by contrast,
parenchymal microglia are CD14–CD45low (REFS 34,35).
All of these cell populations are replenished but with
considerably different lifespans. Perivascular macro-
phages and other macrophages that are close to the
interface with the periphery have a faster turnover than
microglia, perhaps because of this proximity36,37. Tissue
macrophages are terminally differentiated cells, with
some, although limited, mitotic potential. Parenchymal
microglia are much more quiescent, and in mice, it has
been calculated that no more than 20% of the ramified
parenchymal microglia are repopulated throughout the
lifetime of the animal38. Although it is difficult to extrap-
olate these numbers with precision to the longer human
lifespan, the lifespans of perivascular macrophages and
microglia do differ considerably39.
Replenishment of the perivascular-macrophage pop-
ulation by circulating monocytes that migrate into the
brain has the side-effect of ‘opening the door’ to intracel-
lular pathogens. As the monocytes take up residence in
the CNS, they differentiate into macrophages, as they do
in other tissues. Immunohistochemistry and in situ
hybridization studies have conclusively shown that, in the
CNS, the cell population that is most infected by HIV-1
or HIV-2 is the perivascular-macrophage population; this
has also been shown using the rhesus macaque simian
immunodeficiency virus (SIV) model, by examining for
active virus replication and the production of new
virions13–19. Furthermore, MULTINUCLEATED GIANT CELLS
(MNGCs), which are the hallmark of HIV neuropathol-
ogy, express CD14 and CD45, as shown in both HIV
infection and the SIV model17,40.Although these markers
could be expressed after cell fusion, it is reasonable to
assume that some of these infected cells are monocytes
that were infected peripherally and have differentiated
into macrophages in the CNS compartment.
Infection of parenchymal microglia is more contro-
versial, because some investigators do not think that these
cells are ever infected, whereas others do. If CD14 and
MESODERM 
Middle of the three germ layers
of the embryo. It gives rise to the
blood, to the musculoskeletal,
circulatory and urogenital
systems, and to the connective
tissue (including that of dermis),
and it contributes to some
glands.
ECTODERM 
Outer of the three germ layers 
of the embryo. It gives rise to 
the epidermis and most of the
neural tissue.
MONONUCLEAR PHAGOCYTIC
SYSTEM 
Group of bone-marrow-derived
cells with different morphologies
(monocytes, macrophages and
dendritic cells), which are mainly
responsible for phagocytosis,
cytokine secretion and antigen
presentation.
MENINGES 
Surrounding membranes of the
brain and spinal cord. There are
three layers of meninges: the dura
mater (outer), the arachnoid
membrane (middle) and the pia
mater (inner).
MULTINUCLEATED GIANT CELLS 
(MNGCs). Conglomerates 
of cells that form through 
the fusion of infected and
uninfected macrophages 
and microglia. The fusion 
is mediated by HIV-envelope
glycoproteins present at the
surface of infected cells and
CD4 and chemokine receptors
at the surface of uninfected
cells. MNGCs are the
pathological hallmark 
of HIV neuropathology.
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variants that comprise a small minority in the periphery
but are amplified in the absence of strong immunological
pressure.
There is little evidence that the other main CNS cell
types (that is, astrocytes, oligodendrocytes and neurons)
directly participate in virus production, although astro-
cytes support limited infection (BOX 1). Nevertheless,
they participate in HIV neuropathology in more indi-
rect ways, such as by decreasing their ability to remove
toxins; these roles are discussed later.
Chemokines and their receptors in the brain
Because of their role in HIV entry and in many physio-
logical and inflammatory processes, chemokines and
their receptors have received much attention in studies of
the pathogenesis of HAD66. In the CNS, chemokines and
their receptors are involved in the migration, differentia-
tion and activation of some cells and in the proliferation
of glia and neurons. Being essential components of neu-
ronal physiology, they might have a crucial role in the bal-
ance between protection of the CNS (neuroprotection)
and the deleterious neuronal effects (neurodegeneration)
that are characteristic of HAD.
TABLE 2 summarizes the effects of selected chemo-
kines and chemokine receptors with respect to HAD
and neurodegeneration or neuroprotection. All mem-
bers of the CXCR family are expressed in the brain,
mainly by neurons, which show marked increases in
intracellular Ca2+ levels after exposure to α-chemokines
(which bind CXCR-family members), such as CXC-
chemokine ligand 1 (CXCL1; also known as GRO-α)
or CXCL12 (also known as SDF1α and SDF1β)67–72.
CXCR4 and its only ligand CXCL12 are both widely
expressed in the CNS46,68,69,71–75. Members of the CCR
family have also been detected in the brain in both
physiological conditions and during inflammatory
and neurodegenerative diseases; they are mainly
expressed by neuronal-cell subsets, microglia and
astrocytes44,46,68,69,74–79. However, β-chemokines (which
bind CCR-family members) are only weakly expressed
or not expressed in the normal brain.
Neurons themselves release chemokines, such 
as CX
3
C-chemokine ligand 1 (CX
3
CL1; also known as
fractalkine), that might ultimately affect cellular func-
tion in the CNS80–83. However, the most important rela-
tionship between HAD and chemokines occurs in the
macrophage, microglia and lymphocyte populations.
For example, the CD14+CD16+ monocyte subpopula-
tion, which releases high levels of pro-inflammatory
cytokines, is increased in HIV infection40; in contrast to
CD14+CD16– monocytes, these cells express high levels
of CX
3
C-chemokine receptor 1 (CX
3
CR1) and CXCR4,
and they undergo transendothelial migration in resp-
onse to CX
3
CL1 and CXCL12 (REF. 84), indicating a
potential contribution to vascular and tissue injury in
conditions in which cell numbers are increased.
Altered expression of chemokines and chemokine recep-
tors in HIV-infected brains. Altered expression of α- and
β-chemokines in the brain is also a common finding in
HIV encephalitis and could contribute to neuronal
have not yet conclusively proven whether this genetic dif-
ferentiation results from a ‘founder effect’ and reflects
independent entry events or whether it results from spe-
cific adaptation to replication in brain cells, which is
facilitated by the much lower neutralization titres of
antibody in the CNS and possibly by a reduced cytolytic
T-cell response. Furthermore, if replication in the CNS is
more limited, then genetic drift of the viral population in
the CNS is likely to be less marked than in the periphery,
and this has been shown, to some extent, in studies of the
SIV model of CNS disease60.
To test this idea, Ryzhova and co-workers60 ampli-
fied short SIV DNA sequences from single MNGCs
from the brain and compared the sequences obtained
with the sequence of the molecularly cloned inocu-
lum. Remarkably, even two years after infection, there
were sequences that were close or even identical to the
initial inoculum, indicating the persistence of the
original genome in long-lived cells. Although limited
in scope, this study supports the idea that infection of
the parenchymal microglia is possible, because it is
unlikely that virus would persist for such a long time in
a population of cells with a faster turnover, such as
perivascular macrophages. After studying infection
with a chimeric HIV–SIV, Miyake and co-workers61
also argue that the virus genome persists in the brain
throughout infection, but they suggest that there is little
production of infectious virions.
Recently, Gabuzda and colleagues62 have shown that
the envelope glycoprotein of a highly fusogenic, neuron-
apoptosis-inducing, CCR5-using virus required lower
levels of expression of CCR5 and CD4 to mediate cell-
to-cell fusion and infection than the envelope of another
CCR5-using virus that was less pathogenic but similarly
neurotropic. This indicates that a more efficient recep-
tor interaction might be characteristic of a pathogenic
viral phenotype that contributes to the neurodegenera-
tive manifestations of AIDS. These results agree with
our observations that indicate that the gp120 (glyco-
protein 120) of a virus that has been adapted in vitro to
grow in microglia can more efficiently mediate the
infection of cells that express low levels of CD4 (REF. 63)
and has an increased affinity for CD4 (J.M.G. and
F.G.S., unpublished observations). Both the in vitro
adaptation of virus that enables it to grow in microglia
and the generation of neuropathogenic variants have
also been reported in the SIV model64.
Peters et al.65 have also analysed HIV-envelope pro-
teins that have been isolated from both brains (after
autopsy) and lymph-node tissues that were obtained
from HIV-positive individuals with neurological compli-
cations. In general, compared with lymph-node-derived
envelope proteins, brain-derived envelope proteins
showed higher fusogenicity, a tropism for macrophages,
increased ability to infect cells that express only low levels
of CD4 and/or CCR5, and lower sensitivity to a CD4-
specific antibody. These experiments indicate that
specific viral phenotypes might have resulted in vivo
from the adaptation of HIV to replication in the brain
environment, either by selection of variants that arise
from replication in brain macrophages or by selection of
© 2004 Nature Publishing Group
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CXCL12, the interaction of both soluble and virion-
bound gp120 with neuronal CXCR4 elicits marked
increases in intracellular Ca2+ levels and substantial
neurotoxicity92,95,96. However, it is important to note that
such effects have not yet been shown for envelope glyco-
proteins derived from primary HIV isolates or, more
importantly, from isolates obtained from the CNS.
Therefore, although there are clear abnormalities in
the expression of chemokines and their receptors in the
lentivirus-infected CNS, the net effect of these (positive
or negative) has not been conclusively elucidated.
Mechanism of neurodegeneration
Because there is not marked neuronal infection in HAD
(as neurons do not express CD4), other mechanisms
must be implicated in the neuropathological damage of
AIDS (FIG. 3). The expression of chemokines and their
receptors seems to be important for neuronal migration
and development, and for mediating neuronal responses
to survival and apoptotic signals, but chemokines and
their receptors have not been shown to mediate entry of
primary HIV isolates independently of CD4. However,
infection of perivascular macrophages and microglia
(and possibly astrocytes) can cause disruption of normal
neurological functions, either by a direct mechanism
(production of viral proteins such as gp120, Tat (trans-
criptional transactivator) or Vpr (viral protein R) by
infected cells) or by an indirect or ‘bystander’ effect, in
which neurons are damaged mainly as a consequence
of the inflammatory processes. In addition, it has been
proposed that, after the inflammatory process has
‘taken hold’, the viral infection itself might have a more
degeneration and dysfunction73,85,86. Increased expression
of receptors, such as CCR3 and CCR5, has also been
reported in the CNS of macaques infected with SIV and
in the brains of children and adults with AIDS, mostly by
perivascular macrophages and microglia. In adult brain-
tissue samples, microvascular endothelial cells also
expressed CCR3 (REFS 76,78). These observations, together
with the increased expression of β-chemokines in the
brains of monkeys with SIV encephalitis87,88 and in the
CNS of patients with HIV encephalitis86,89,90, might
support a role for chemokines in the development of
neuropathogenesis. However, the effects of selected
chemokines on neuronal function might be either posi-
tive or negative. No neurotoxic effects of β-chemokines
have been shown so far in vivo, whereas several in vitro
studies have shown that β-chemokines, such as CC-
chemokine ligand 4 (CCL4; also known as MIP1β)
and CCL5 (also known as RANTES), can protect cul-
tured neurons from apoptosis that is induced by gp120
(REFS 69,83,91).
The α-chemokines CXCL10 (also known as IP10)
and CXCL12 also seem to be present at increased levels
in the CSF and brain of HIV-infected individuals and
might be implicated in neuropathogenesis75,85,92,93.
However, their effects are unclear, because they seem to
depend on in vitro culture conditions85,91–93, and modu-
lation of the expression levels of their receptors might
also influence neuronal responses. So, neurons cultured
in the presence of fibroblast growth factor showed a
dose-dependent decrease in expression of CXCR4,
which might result in decreased neurotoxicity of HIV
gp120 (REF. 94). In contrast to its chemokine ligand
Box 1 | Involvement of CNS cells (other than macrophages and microglia) in HIV infection
Astrocytes
Astrocytes are responsible for maintaining homeostasis in the central nervous system (CNS). They express receptors
that enable them to respond to almost all known neuroactive compounds, including neurotransmitters. Through these
receptors, astrocytes also function as CNS sentinels and regulate the levels of neurotransmitters, such as glutamate.
In addition, astrocytes help to establish and maintain CNS boundaries, such as the blood–brain barrier, through their
interactions with endothelial cells. Tissue damage, as seen in the brains of HIV-infected patients, results in a strong
proliferative response by astrocytes166,167.
Astrocytes might be infected by HIV to some extent, although any infection of astrocytes is unlikely to result in robust
viral replication, because few astrocytes are found to express viral antigens. The mechanism of viral entry to astrocytes is
unclear, because they do not express detectable levels of cell-surface CD4 or the main HIV co-receptors, and the process
of infection seems to be insensitive to inhibition by either chemokines or antibodies specific for CD4 or the chemokine-
receptor-binding site of gp120 (REF. 168). In patients with HIV-associated dementia (HAD), astrocytosis that is induced
by viral proteins and macrophage products might have a role in the loss of astrocytic function and brain homeostasis,
leading to neuropathogenesis13,14,169.
Oligodendrocytes
Oligodendrocytes produce the myelin sheath, a lipid- and protein-rich membrane that promotes fast axonal conduction.
There is no evidence of oligodendrocyte infection in vivo, although the binding of gp120 to galactosylceramide or other
proteoglycans might reduce myelin synthesis and increase intracellular Ca2+ levels and apoptotic-cell numbers, as has
been shown in vitro170.
Neurons
As the main effectors of cognitive and motor function, neurons must be involved in HIV neuropathogenesis, and indeed,
there is significant neuronal cell death in HIV-infected brains171–173. However, there are no traces of neuronal infection in
patients with HAD, although there are other effects (for details, see the main text).Accordingly, neurons do not express
CD4, although different subsets express some of the chemokine receptors that are co-receptors for HIV infection46,66,73.
These seem to be important for neuronal migration and development, and for neuronal responses to survival and
apoptotic signals, but they have not been shown to mediate HIV entry.
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as a co-receptor; by contrast, most of the isolates from
the CNS that have been described so far use CCR5 as a
co-receptor. In addition, most studies have used
monomeric gp120 and not the physiological form of
the protein, which is a trimer. Furthermore, previous
interaction with CD4 is required for gp120 to bind the
cellular co-receptor. Therefore, the in vivo relevance of a
direct interaction between gp120 and chemokine recep-
tors at the cell surface of neurons and the subsequent
neuronal apoptosis remains to be proven. gp120 can
also induce neuronal cell death through direct interac-
tion with the NMDA (N-METHYL-D-ASPARTATE) receptor98–101
or by a mechanism that involves the production of
limited role in the degenerative process, having estab-
lished a self-sustaining ‘chain reaction’. Although these
two mechanisms are not mutually exclusive and might
coexist, in our opinion the bystander theory is more
consistent with most of the evidence.
Direct injury hypothesis. In in vitro experiments, HIV
gp120 interacts with chemokine receptors, which leads
to neuronal injury; this might indicate that it is the
release of this viral protein that mediates neuronal cell
death69,83,85,91,92,97. Although this hypothesis is appeal-
ing, most studies that show this interaction have used
gp120 proteins derived from isolates that use CXCR4
N-METHYL-D-ASPARTATE 
(NMDA). Amino-acid derivative
that functions as a specific
agonist of the NMDA receptor
and therefore mimics the action
of the neurotransmitter
glutamate on that receptor. In
contrast to glutamate, it binds
and opens only the NMDA
receptor and not other
glutamate receptors.
Table 2 | Role of selected chemokines and chemokine receptors in HIV-associated dementia
Chemokine Cellular sources Effects in the brain Chemokine Location of receptor
receptor(s) expression in brain
CXCL8 Activated astrocytes and microglia Modulation of synaptic transmission and CXCR1 Microglia, subsets of 
(IL-8) (induced by HIV Tat) plasticity; and inhibition of long-term neurons, astrocytes
potentiation* in hippocampus and oligodendrocytes
CXCR2 Microglia, neurons
astrocytes, and 
oligodendrocyte
precursors
CXCL10 Astrocytes (induced by HIV Tat), Alteration of synaptic plasticity in CXCR3 Microglia, subsets of 
(IP10) microglia and brain endothelial cells; hippocampus; and induction of neurons, and astrocytes
increased in SHIV encephalitis leukocyte infiltration
CXCL12 Astrocytes, microglia, specific neurons Promotion of neuronal migration during CXCR4 Microglia, neurons,
(SDF1α, from select anatomical regions (cortical cerebellar development, microglial astrocytes and
SDF1β) neurons and cerebellar granule cells), chemotaxis and mesenchymal stem-cell endothelial cells
injured neurons; overexpressed in migration to site of injury; promotion of
gliomas survival or apoptosis of hippocampal
neurons; regulation of cholinergic and
dopaminergic systems; promotion of 
astrocyte proliferation; and promotion 
of cytokine and glutamate release
CCL2 Astrocytes and microglia in patients Protection of neurons and astrocytes CCR2 Human fetal glia and
(MCP1) with AIDS and in SHIV-induced from NMDA- or HIV Tat-induced neurons, astrocytes 
encephalitis (induced by Tat); apoptosis, through release of astrocyte and NT2.N cells
increased levels in CSF of patients growth factors
with HAD
CCL3 Microglia, neurons, astrocytes and Development of CNS; migration of CCR1 Subsets of neurons,
(MIP1α) oligodendrocytes (in Alzheimer’s disease), astrocytes and microglia; recruitment astrocytes and
glia and macrophages (in multiple of monocytes to brain parenchyma oligodendrocyte 
sclerosis); increased levels in patients in patients with HAD or other precursors
with HAD and in SIV encephalitis neurological disorders CCR5 Microglia, neurons
and astrocytes
CCL4 Increased levels in patients with HAD Recruitment of monocytes to brain CCR5 Microglia, neurons 
(MIP1β) and macaques with SIV encephalitis; parenchyma; involvement in migration and astrocytes
might decrease infection of of macrophages, microglia and astrocytes
macrophages and microglia
CCL5 Astrocytes, macrophages and Recruitment of monocytes to brain CCR1, CCR3 Microglia, neurons  
(RANTES) microglia; higher levels in HIV parenchyma; involvement in migration and CCR5 and astrocytes
infection and SIV encephalitis of macrophages, microglia and astrocytes
CCL7 Astrocytes in patients with HAD Recruitment of monocytes to CCR1, CCR2 Microglia, neurons 
(MCP3) and macaques with SIV encephalitis; brain parenchyma and CCR3 and astrocytes
absent in normal human brain
CX3CL1 Neurons (upregulated during injury) Recruitment of receptive cells CX3CR1 Microglia, subsets of 
(Fractalkine) and endothelial cells; for astrocytes (mainly microglia), when in soluble neurons, astrocytes
and microglia, can be upregulated  form; polymorphisms affect the and endothelial cells
by TNF and IL-1β development of AIDS
*Long-term potentiation is a persistent increase in the size of the synaptic response that is induced by several mechanisms; in the hippocampus, it is thought to be the synaptic
basis of learning and memory in vertebrates. CCL, CC-chemokine ligand; CCR, CC-chemokine receptor; CNS, central nervous system; CSF, cerebrospinal fluid; CXCL, CXC-
chemokine ligand; CX3CL1, CX3C-chemokine ligand 1; CXCR, CXC-chemokine receptor; CX3CR1, CX3C-chemokine receptor 1; HAD, HIV-associated dementia; IL, interleukin;
IP10, interferon-γ-induced protein of 10 kDa; MCP, monocyte-chemotactic protein; MIP1, macrophage inflammatory protein 1; NMDA, N-methyl-D-aspartate; RANTES,
regulated upon activation, normally T-cell expressed and presumably secreted; SDF1, stromal-cell-derived factor 1; SHIV, simian–human immunodeficiency virus; SIV, simian
immunodeficiency virus; Tat, transcriptional transactivator; TNF, tumour-necrosis factor.
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same caveats as gp120, with the additional concerns that
viral replication in the CNS is limited and that a protein
that mediates its effect intracellularly might not be abun-
dantly secreted — despite in vitro or systemic evidence to
the contrary. Tat has also been shown to alter tight-
junction protein expression and BBB function and to
upregulate expression of many inflammatory mediators
that promote monocyte infiltration into the brain, such
as CCL2 (also known as MCP1); it has also been shown
to be neurotoxic through mechanisms that involve mul-
tiple intracellular-signalling pathways106–109. So, if Tat is
present as free protein in high quantities in vivo, it could
contribute to the neuronal injury seen in HAD.
The function of Vpr is more difficult to summa-
rize: it induces cell-cycle arrest, promotes transcrip-
tion, facilitates nuclear import of the PRE-INTEGRATION
COMPLEX, and when secreted, it might have a role in
pathogenesis, because it has been shown to activate
replication in latently infected cells and to induce the
tumour-necrosis factor (TNF) by non-neuronal cells,
with subsequent activation of caspase-mediated cell
death of neurons through interaction with the TNF
receptors (TNFRs)102,103. Therefore, gp120 might have a
role in further stimulation of macrophages and
microglia, rather than in directly injuring neurons,
thereby contributing to the general increase in cellular
activation that is characteristic of the neuropathology
of HAD. However, an important unanswered question
is whether the concentrations of gp120 that are present
in the CNS are high enough to mediate the effects
observed in cultured cells104.
Two other viral proteins, Tat and Vpr, have also
been suggested as potential effectors in HAD. Tat
exerts its main activity in the nucleus and is effective at
low concentrations, although it can be secreted at high
levels in vitro105. Secreted Tat might cause direct injury to
neurons; however, its presence as a free protein in body
fluids or serum has not been shown and is subject to the
PRE-INTEGRATION COMPLEX 
Ensemble of the viral RNA
genome that is present in 
the virion (which consists 
of the nucleocapsid protein,
the structural protein p6,
the accessory protein Vpr, the
integrase protein and several
copies of the matrix protein),
where the synthesis of viral
DNA occurs. By engaging
cellular proteins, the viral 
DNA can then be transported
to the nucleus, where it can 
be integrated into the genome
of the host cell.
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Figure 3 | Mechanisms of neurodegeneration and neuroprotection in AIDS. a | Infected perivascular macrophages and
microglia are responsible for producing HIV but might also release viral proteins that can be deleterious to the central nervous
system. The HIV-envelope protein gp120 (glycoprotein 120), Tat (transcriptional transactivator) and Vpr (viral protein R) have all
been shown to be toxic in vitro to neurons and/or astrocytes, although their relevance in vivo is unknown. Infected and activated
cells also produce other factors — such as cytokines (including tumour-necrosis factor, TNF), quinolinic and arachidonic acid,
platelet-activating factor (PAF) and nitric oxide — that are known to have neurotoxic effects. b | Importantly, they promote the
further activation (and to some extent, proliferation) of macrophages and/or microglia, as well as the proliferation and activation 
of astrocytes. c | Activated astrocytes modify the permeability of the blood–brain barrier and promote the migration of more
monocytes into the brain. d | In addition, through increases in release of intracellular Ca2+ and glutamate and through decreases
in glutamate uptake, the brain concentration of glutamate and other neurotoxins increases and results in excitotoxic death of
neurons. e | However, activation of macrophages and/or microglia, and TNF-mediated activation of astrocytes, also results in 
the release of β-chemokines, CX3C-chemokine ligand 1 (CX3CL1) and growth factors, all of which are known to regulate Ca2+
homeostasis in neurons, to promote anti-apoptotic signalling pathways and to decrease gp120-mediated and excitotoxic
neuronal cell death, thereby promoting neuronal survival. Grey arrows indicate neuroprotective pathways.
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as a neurotoxin is still under debate, because in vitro
studies show that it can also be neurotropic134,135. As a
toxin, TNF functions in an autocrine manner to pro-
mote the activation of the mitogen-activated protein
kinase (MAPK) p38, resulting in the production of more
TNF136. Astrocytes also produce TNF and other inflam-
matory cytokines after activation137, resulting in a feed-
back mechanism that amplifies excitotoxic glutamate
release and decreases glutamate uptake by the astrocytes
themselves102. The presence of high levels of glutamate or
other excitatory molecules in the vicinity of neurons
causes uncontrolled Ca2+ influx, loss of cellular homeo-
stasis and neuronal-cell death through apoptosis138. This
Ca2+-dependent killing seems to be common to many
neurodegenerative disorders.
Christopher Power’s research group139 recently pro-
posed an interesting model that involves many of these
toxic molecules. They identified a neurotoxic cleavage
product of CXCL12 (amino acids 5–67) and propose
that it is produced by the activity of matrix metallo-
proteinase 2. This protease is secreted by macrophages
or microglia that are infected by HIV124,125. This model
takes into account the presence of chemokine recep-
tors, in particular CXCR4, at the cell surface of neu-
rons, but in contrast to other proposed mechanisms, it
depends on viruses that use CCR5 as a receptor
(which, in the CNS, are the most abundant ).
In contrast to these studies, there is a growing body of
work that indicates that microglial activation and specific
T-cell subpopulations in the brain can have neuroprotec-
tive effects30,31. TNF might also have a neuroprotective
role against toxicity and prevent or attenuate Ca2+ accu-
mulation in the cytosol of neurons140–144. In addition,
TNFR activation of signalling that involves the anti-
apoptotic kinase AKT (also known as PKB; an important
component of pro-survival signalling pathways) and
nuclear factor-κB (NF-κB)141,142,145 results in alterations
in gene expression that are crucial for the response of
neurons to insults142,146. Furthermore, β-chemokines and
CX
3
CL1 have also been shown to protect neurons from
the toxicity induced by the interaction of gp120 with its
receptor; this protection is mediated by phosphatidyl-
inositol-3-kinase-dependent activation of AKT and
nuclear translocation of downstream NF-κB83,91. These
data indicate that neuronal chemokine receptors mediate
the neurotropic effects of β-chemokines and CX
3
CL1.
Because TNF induces the production of β-chemokines
by activated glia and of CX
3
CL1 by astrocytes147,148, it is
probable that these cytokines and chemokines are
involved in a complex network of both paracrine and
autocrine interactions between neurons and glia.
However, it is also probable that the various effects of
TNF in vivo depend on the length and the intensity of
the exposure of the cells to TNF. And they are also likely
to depend on the ratio of TNFR1 to TNFR2 expression
by specific cells, because it has been shown that, depend-
ing on the cell type and the levels of expression of these
two types of TNFR (which are highly regulated), TNF
can either mediate similar effects through different
intracellular-signalling pathways or mediate completely
different functional consequences149.
killing of bystander cells110. In the CNS, both intracellular
and extracellular Vpr have been shown to induce apopto-
sis of human neuronal-precursor cells (the NT2 cell line)
and of mature, differentiated neurons, through a caspase-
8-dependent mechanism111,112. In contrast to Tat,Vpr has
been detected in the CSF of patients with HIV113, but the
caveats regarding appropriate concentrations also apply
in this case.
Bystander effect hypothesis. Despite these findings, it is
possible that HIV infection is only part of the picture;
HIV encephalitis is associated with immune activation
that seems to be out of proportion to the amount of
virus that is present, and inflammation itself results in
modification of the extracellular secretory functions of
microglia and brain macrophages (FIG. 3). Chemokines,
pro-inflammatory cytokines — such as TNF and
interleukin-1β (IL-1β) — and other soluble products
lead to the activation of uninfected cells20,21,91 and to the
migration of HIV-specific, activated T cells into the
CNS114,115, thereby contributing to the amplification of
HIV-induced neurotoxicity.Accordingly, progression to
HAD has been correlated with the following: increased
expression of macrophage activation markers116, synthesis
by macrophages and microglia of quinolinic and arachi-
donic acids and related metabolites117, increased produc-
tion of TNF118, increased expression of mRNA encoding
inducible nitric-oxide synthase, increased production of
free radicals119–122, and proliferation and apoptosis of
astrocytes123. In addition, some of these macrophage
products can also modify the permeability of the BBB
and induce the expression of adhesion molecules by
endothelial cells, thereby promoting further monocyte
migration into the brain. Moreover, the overexpression
of MATRIX METALLOPROTEINASES in HIV-infected individuals
and in HIV and SIV models124–126, as well as the over-
expression of intercellular adhesion molecule 1 (ICAM1)
and vascular cell-adhesion molecule 1 (VCAM1) in the
brains of patients with HAD127–129, have been described.
Although astrocytes are secondary components in
this complex scenario (because they are not produc-
tively infected by HIV), the interaction between infected
macrophages and astrocytes inhibits important protec-
tive astrocytic functions, such as the uptake of excitatory
amino acids (for example, glutamate).As previously dis-
cussed, increased expression of both pro-inflammatory
and non-inflammatory cytokines (including transform-
ing growth factor-β (TGF-β), IL-1α, IL-1β, IL-6 and
TNF) has been documented in the brain and/or CSF
of patients with AIDS, particularly of those with
HAD117,118,130–132. However, it has also been reported that
the co-culture of astrocytes with HIV-infected macro-
phages might decrease the levels of neurotoxins that are
released by these macrophages133. This argues against the
long-standing hypothesis that reactive astrocytes
respond to insults only by producing glial scars and by
affecting neuronal survival, and it implies that the process
is exceedingly complex and that the final equilibrium
depends on as-yet-undefined factors.
For example, although TNF is a macrophage-
secretion product that is involved in HAD, its activity
MATRIX METALLOPROTEINASES 
Peptide hydrolases that use 
a metal for their catalytic
mechanism and degrade the
extracellular matrix. They have
an important role in several
neurodegenerative processes.
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(molecules that carry out the apoptotic programme)
and the MAPK p38 have been targeted by specific inhi-
bitors, and these have been shown to prevent neuronal
loss that can be induced by excitotoxicity, gp120 or the 
α-chemokine CXCL12 (REFS 91,160–163). Overexpression of
the anti-apoptotic protein BCL-2 (B-cell lymphoma 2),
which suppresses p38 and NF-κB activation, has been
found to reduce neuronal β-amyloid-induced cell
death; indeed, p38- and NF-κB-specific inhibitors also
have been shown to attenuate neuronal apoptosis by
upregulating the expression of BCL-2 (REF. 164). The
anti-apoptotic effects of BCL-2 were also shown in rela-
tion to the neurotoxic effects induced by HIV, as upreg-
ulation of BCL-2 gene expression has been found to
confer neuroprotection and to counteract the neuro-
toxicity that is induced by supernatants from HIV-
infected macrophages165. Other similar approaches
might be useful in future.
Concluding remarks
In developed countries, the impressive effects of HAART
have converted AIDS from a fatal disease to a more
manageable chronic infection, and they have led to the
hope that, with aggressive therapy, the virus could be
completely eradicated. Unfortunately, regions that
remain relatively isolated from the systemic circulation,
such as the CNS, might provide a ‘sanctuary’ for latent
or slowly replicating virus. Although the incidence of
HAD has diminished considerably, there is still a pop-
ulation of patients that, despite therapy, are more
prone to developing MCMD, together with its poten-
tially negative consequences. So, MCMD raises the
possibility that HIV is replicating at low levels in the
CNS and providing a barrier to the complete eradica-
tion of the virus. In addition, with time, this trouble-
some, but not ‘lifestyle-defining’, problem could evolve
into a ‘full-blown’ dementia-inducing process, particu-
larly in a population that is now older, having survived
the opportunistic infections that characterized the
early periods of the AIDS epidemic. Both HAD and
MCMD therefore require therapies that are specifically
tailored to protect the brain from the effects of viral
infection and, in particular, from the consequences of
the inflammatory process.
In this review, we have emphasized the importance
of bone-marrow-derived cells and their potentially
toxic products in the development of CNS dysfunction
during infection with HIV. Furthermore, given that
some mediators might be neuroprotective, such as
TGF-β, future therapeutic efforts should also target
these novel neuroprotective mechanisms to attempt to
reverse some of the negative effects of immune activation.
Whereas the effects mediated by TNF might be either
beneficial or deleterious, TGF-β1 has been shown to be
neuroprotective101,150. Therefore, the increased levels of
TGF-β1 in the brain of patients with HAD131,151 are likely
to be neuroprotective.
Potential avenues for therapeutic intervention
The need for specific therapies for CNS complications
of HIV infection largely depends on two unknown fac-
tors: whether the brain is a long-term reservoir for HIV;
and whether MCMD, and other less severe forms of
encephalopathy, will progress despite effective systemic
HAART. Only further study of the HIV epidemic will
resolve these questions. At present, we know that,
although the probable latent infection of microglia and
other long-lived cells supports the concept that HIV
might reside in the CNS in a semi-protected state, viral
re-entry from the CNS into the systemic circulation has
not been shown. MCMD is indeed a chronic manifesta-
tion of HIV in the CNS, and it could progress to a more
severe dementia. However, further studies are necessary
to determine this, because in the short term, the inci-
dence of dementia has remained low in patients being
treated with HAART.
The penetration of the currently used antiretrovi-
ral drugs into the CNS is variable, and protease
inhibitors are specifically excluded from the CNS by
the BBB6. Newly developed chemokine-receptor
antagonists and entry inhibitors could help reduce the
viral load in the brain, provided that they can cross
into the CNS; this also applies to new reagents that are
being developed, such as inhibitors of the viral inte-
grase protein152–154. However, because neuronal apop-
tosis might be more dependent on cellular activation
and secondary products than on the total amount of
virus or viral proteins in the brain, if a specific therapy
is developed, it will probably need to be directed to
the ‘amplification’ mechanisms of the virus, rather
than to the virus itself.
The use of NMDA-receptor antagonists and anti-
oxidants are good examples of this approach. The
NMDA-receptor antagonist memantine, an open-
channel blocker, has been shown to prevent excessive
NMDA-receptor activity and to attenuate the neuronal
damage induced by HIV-infected macrophages and
gp120 (REFS 155–157); it is now approved for therapy for
Alzheimer’s disease158,159. Anti-oxidants could be useful
to reduce direct damage by nitric oxide and to reduce
the effect of nitric oxide on promoting HIV replication
in monocytoid cells122.
Another approach might be to directly target the
mechanisms involved in neuronal apoptosis. Caspases
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